Primary Site >> Esophagus Cancer
Gene >> ERBB2
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Biological significance of gene amplification in carcinogenesis. PMID: 1844251 Ref: [Cancer metastasis and recurrence from the standpoint of amplification and expression of oncogenes in human malignant tumors]. PMID: 1944161 |
Ref: Frequent expression of the tumor antigen CAK1 in squamous-cell carcinomas. PMID: 1351045 |
Ref: Expression of c-erbB-2 in human esophageal carcinoma cells: overexpression correlated with gene amplification or with GATA-3 transcription factor expression. PMID: 7902061 |
Ref: Epidermal growth-factor receptors and erbb2 protein expression in esophageal cancer and normal mucosa. PMID: 21597745 |
Ref: Coexpression of Grb7 with epidermal growth factor receptor or Her2/erbB2 in human advanced esophageal carcinoma. PMID: 8988034 Ref: Isolation of a candidate gene, CAB1, for cholesterol transport to mitochondria from the c-ERBB-2 amplicon by a modified cDNA selection method. PMID: 9270027 |
Ref: Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. PMID: 10499598 Ref: Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. PMID: 10512940 |
Ref: Akt/protein kinase B isoforms are differentially regulated by epidermal growth factor stimulation. PMID: 10908564 |
Ref: Metastatic adenocarcinoma of the esophagus to the skin: new patterns of tumor recurrence and alternate treatments for palliation. PMID: 11493381 Ref: Tumor marker expression is predictive of survival in patients with esophageal cancer. PMID: 11565671 |
Ref: Primary adenocarcinomas of lower esophagus, esophagogastric junction and gastric cardia: in special reference to China. PMID: 12800215 Ref: [Effect of trastuzumab for human esophageal cancer]. PMID: 14619518 Ref: c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. PMID: 14630269 |
Ref: Gene expression profiles in esophageal adenocarcinoma. PMID: 14992916 Ref: ERBB2 amplifications in esophageal adenocarcinoma. PMID: 15511476 |
Ref: Monoclonal antibody to HER-2/neu receptor enhances radiosensitivity of esophageal cancer cell lines expressing HER-2/neu oncoprotein. PMID: 15629613 Ref: Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival. PMID: 15693850 Ref: Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. PMID: 15737843 Ref: Mechanism of action of (-)-epigallocatechin-3-gallate: auto-oxidation-dependent inactivation of epidermal growth factor receptor and direct effects on growth inhibition in human esophageal cancer KYSE 150 cells. PMID: 16140980 |
Ref: Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers. PMID: 16490596 |
Ref: The pan-erbB tyrosine kinase inhibitor CI-1033 inhibits human esophageal cancer cells in vitro and in vivo. PMID: 17342332 Ref: Collision carcinoma of the residual cervical esophagus 27 years after esophageal cancer surgery. PMID: 17348434 |
Ref: Genomic profiling of 766 cancer-related genes in archived esophageal normal and carcinoma tissues. PMID: 18241037 Ref: Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. PMID: 18455127 Ref: HER2 amplification in micrometastatic esophageal cancer cells predicts prognosis. PMID: 18691587 |
Ref: Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. PMID: 19302210 Ref: Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432. PMID: 19761832 Ref: Peripheral position of CCND1 and HER-2/neu oncogenes within chromosome territories in esophageal and gastric cancers non-related to amplification and overexpression. PMID: 21637674 |
Ref: Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus. PMID: 20104520 Ref: Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. PMID: 20679611 |
Ref: Functional polymorphisms associated with disease-free survival in resected carcinoma of the esophagus. PMID: 20922573 Ref: Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. PMID: 21207425 Ref: Her-2/neu gene amplification in esophageal adenocarcinoma and its influence on survival. PMID: 21267790 Ref: Detection of erbB2 copy number variations in plasma of patients with esophageal carcinoma. PMID: 21481261 Ref: Update on HER2 testing for breast and upper gastrointestinal tract cancers. PMID: 21657840 Ref: Orthotopic models of esophageal carcinoma and their use in drug discovery. PMID: 21898333 |
Ref: Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. PMID: 21318736 Ref: HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options. PMID: 21745161 Ref: Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment. PMID: 21783379 Ref: Characteristics of double heterozygosity for BRCA1 and BRCA2 germline mutations in Korean breast cancer patients. PMID: 21847643 Ref: Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. PMID: 22293713 Ref: Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. PMID: 22450065 Ref: Current developments in the management of locally advanced esophageal cancer. PMID: 22544559 Ref: Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. PMID: 22751462 Ref: Cap-dependent mRNA translation and the ubiquitin-proteasome system cooperate to promote ERBB2-dependent esophageal cancer phenotype. PMID: 22767218 Ref: Targetting esophageal and gastric cancers with monoclonal antibodies. PMID: 22978338 Ref: [Update on Barrett esophagus and Barrett carcinoma]. PMID: 23011020 Ref: Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study. PMID: 23052161 Ref: Involvement of CXCR4 chemokine receptor in metastastic HER2-positive esophageal cancer. PMID: 23082154 Ref: Adenocarcinoma of the GEJ: gastric or oesophageal cancer? PMID: 23129369 |
Ref: Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma. PMID: 22458639 Ref: Correlation analysis of c-myc, p21(WAF/CIP1), p53, C-erbB-2 and COX-2 proteins in esophageal squamous cell carcinoma. PMID: 23177619 Ref: Targeted therapies with chemoradiation in esophageal cancer: development and future directions. PMID: 23207045 Ref: Expression status of fatty acid synthase (FAS) but not HER2 is correlated with the differentiation grade and prognosis of esophageal carcinoma. PMID: 23419663 Ref: Primary high-grade neuroendocrine carcinoma of the esophagus: a clinicopathologic and immunohistochemical study of 42 resection cases. PMID: 23426118 Ref: Overcoming regulatory T-cell suppression by a lyophilized preparation of Streptococcus pyogenes. PMID: 23436617 Ref: The expression of Egfl7 in human normal tissues and epithelial tumors. PMID: 23558933 Ref: Chemotherapeutic and targeted strategies for locally advanced and metastatic esophageal cancer. PMID: 23591158 Ref: Emerging tyrosine kinase inhibitors for esophageal cancer. PMID: 23725567 Ref: Testing the utility of an integrated analysis of copy number and transcriptomics datasets for inferring gene regulatory relationships. PMID: 23737949 Ref: [A case of advanced esophagogastric junction cancer responding to pre-operative combination chemotherapy of docetaxel, cisplatin, S-1, and trastuzumab]. PMID: 23986058 Ref: Preoperative treatment of locally advanced esophageal carcinoma (Review). PMID: 24100679 Ref: Advances in biomarkers for esophageal cancer. PMID: 24134419 Ref: Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. PMID: 24222138 Ref: The MAPK pathway is a predominant regulator of HLA-A expression in esophageal and gastric cancer. PMID: 24244023 |
Ref: HER2 status in Barrett's esophagus & esophageal cancer: a meta analysis. PMID: 24490040 Ref: EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer. PMID: 24510732 Ref: An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer. PMID: 24664246 Ref: The clinical utility of circulating tumor cells in breast cancer patients: detection by a quantitative assay of h-MAM gene expression. PMID: 24706379 Ref: HER2 directed therapy for gastric/esophageal cancers. PMID: 24811128 Ref: New directions in perioperative management of locally advanced esophagogastric cancer. PMID: 24857100 Ref: Establishment and characterization of esophageal squamous cell carcinoma patient-derived xenograft mouse models for preclinical drug discovery. PMID: 24999713 Ref: Prediction of response to endoscopic therapy of Barrett's dysplasia by using genetic biomarkers. PMID: 25085335 Ref: ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways. PMID: 25091467 Ref: The potential for targeting HER2 therapeutically in esophageal cancer - a grasp at straws? PMID: 25256600 Ref: MicroRNA signatures in chemotherapy resistant esophageal cancer cell lines. PMID: 25356050 Ref: HER2-positive, trastuzumab-resistant metastatic esophageal cancer presenting with brain metastasis after durable response to dual HER2 blockade: a case report. PMID: 25436131 |
Ref: A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage. PMID: 25214541 Ref: ErbB2 signaling activates the Hedgehog pathway via PI3K-Akt in human esophageal adenocarcinoma: identification of novel targets for concerted therapy concepts. PMID: 25435423 Ref: Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. PMID: 25480824 Ref: Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. PMID: 25694417 Ref: Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. PMID: 25778705 Ref: Appropriateness of using patient-derived xenograft models for pharmacologic evaluation of novel therapies for esophageal/gastro-esophageal junction cancers. PMID: 25826681 Ref: HER2 expression in gastric and oesophageal cancer: a meta-analytic review. PMID: 25830034 Ref: Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. PMID: 26336083 Ref: Molecular Marker Expression Is Highly Heterogeneous in Esophageal Adenocarcinoma and Does Not Predict a Response to Neoadjuvant Therapy. PMID: 26394876 Ref: Synchronous Tumors: Adenocarcinoma of the Esophagus and Clear Cell Renal Carcinoma. PMID: 26411176 Ref: In vivo multiplexed molecular imaging of esophageal cancer via spectral endoscopy of topically applied SERS nanoparticles. PMID: 26504623 Ref: Perioperative and Palliative Chemotherapy for Esophageal Cancer. PMID: 26989390 |
Ref: Gastric Carcinoma at the Era of Targeted Therapies. PMID: 25944013 Ref: Pertuzumab in gastrointestinal cancer. PMID: 26619359 Ref: Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer. PMID: 26857264 Ref: ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3. PMID: 26863569 Ref: Genomic Landscape of Esophageal Squamous Cell Carcinoma in a Japanese Population. PMID: 26873401 Ref: Targeted therapy in esophageal cancer. PMID: 26895097 Ref: Evaluation of the diagnostic value of 64 simultaneously measured autoantibodies for early detection of gastric cancer. PMID: 27140836 Ref: MiR-193a-5p/ERBB2 act as concurrent chemoradiation therapy response indicator of esophageal squamous cell carcinoma. PMID: 27203740 Ref: Role of human epidermal growth factor receptor 2 as a prognostic factor for survival in esophageal carcinoma: evidence from 2872 subjects. PMID: 27309036 Ref: New Strategies in Esophageal Carcinoma: Translational Insights from Signaling Pathways and Immune Checkpoints. PMID: 27370606 Ref: An update in the nonendoscopic treatment of gastric cancer. PMID: 27636304 Ref: Molecular Markers for the Prediction of Minor Response to Neoadjuvant Chemoradiation in Esophageal Cancer: Results of the Prospective Cologne Esophageal Response Prediction (CERP) Study. PMID: 27741011 Ref: [Epigenetic markers of esophageal cancer: DNA methylation]. PMID: 27797326 Ref: Trastuzumab in the management of gastroesophageal cancer: patient selection and perspectives. PMID: 27932891 Ref: Tumor profiling of co-regulated receptor tyrosine kinase and chemoresistant genes reveal different targeting options for lung and gastroesophageal cancers. PMID: 28078044 |
Ref: HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. PMID: 27811012 Ref: The angiotensin II type 1 receptor antagonist telmisartan inhibits cell proliferation and tumor growth of esophageal adenocarcinoma via the AMPKalpha/mTOR pathway in vitro and in vivo. PMID: 28052030 Ref: Translating genomic profiling to gastrointestinal cancer treatment. PMID: 28067073 Ref: Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. PMID: 28271259 Ref: Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition. PMID: 28286209 Ref: The Prolyl Isomerase Pin1 Is a Novel Target of 6,7,4'-Trihydroxyisoflavone for Suppressing Esophageal Cancer Growth. PMID: 28325828 Ref: Esophageal Cancer: New Insights into a Heterogenous Disease. PMID: 28384630 Ref: Perspectives of HER2-targeting in gastric and esophageal cancer. PMID: 28387541 Ref: The adjuvant value of Andrographis paniculata in metastatic esophageal cancer treatment - from preclinical perspectives. PMID: 28405006 Ref: Tyrosine kinase inhibitor induced growth factor receptor upregulation enhances the efficacy of near-infrared targeted photodynamic therapy in esophageal adenocarcinoma cell lines. PMID: 28415738 |
Ref: Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. PMID: 29037469 Ref: Diagnostic pathology of early systemic cancer: ERBB2 gene amplification in single disseminated cancer cells determines patient survival in operable esophageal cancer. PMID: 29044505 Ref: HER2 Confers Resistance to Foretinib Inhibition of MET-Amplified Esophageal Adenocarcinoma Cells. PMID: 29223420 Ref: [Surgical treatment and prognosis of Borrmann type IIII( gastric cancer involving the whole stomach]. PMID: 29492918 Ref: Surgery for metastases for esophageal-gastric cancer in the real world: Data from the AGAMENON national registry. PMID: 29685755 Ref: Tribody [(HER2)2xCD16] Is More Effective Than Trastuzumab in Enhancing gammadelta T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. PMID: 29725336 Ref: Esophageal cancer cells resistant to T-DM1 display alterations in cell adhesion and the prostaglandin pathway. PMID: 29765526 Ref: CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target. PMID: 29865880 Ref: miR-143 Regulates Memory T Cell Differentiation by Reprogramming T Cell Metabolism. PMID: 30150287 Ref: Absence of HER2 Expression of Circulating Tumor Cells in Patients with Non-Metastatic Esophageal Cancer. PMID: 30275185 |